Abstract
Purpose :
The aim of the study is to know the prevalence of VEGF polymorphisms (-634 C/G) and its relationship with therapeutic success in patients with diabetic macular edema.
Methods :
We conducted a prospective, longitudinal study. , We analyzed 81 samples of patients treated with intravitreous bevacizumab, peripheral blood DNA extraction was performed with the labeling of the VEGF gene promoter region -634, they were cataloged in responders and non-responders depending on Central macular thickness measured with OCT (Heidelberg) baseline, first and third month post injection, and analyzed for the genotype frequency.
Results :
Analyzing the genotype frequency, we can observe an adequate response rate of 33% in GG (-634), GC 57% and CC only 10%. The presence of CC genotype presents a relative risk of 2.35 times less response to antiangiogenic treatment compared to GG genotype.
Conclusions :
In our study, the presence of VEGF-634 C / C polymorphism is more frequent in Latino patients with poor response to treatment of diabetic macular edema with intravitreal bevacizumab
This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.